Title: Long-term opioid therapy definitions and predictors: a systematic review

Running title: Long-term opioid therapy review

Authors: Ruchir N Karmali PhD^{a,b,c,d}, Christopher Bush MPH^a, Sudha R Raman PhD^{a,b}, Cynthia I. Campbell, PhD^d, Asheley C Skinner PhD^{a,b}, Andrew W Roberts PharmD, PhD^{e,f}

Affiliations: ^a Department of Population Health Sciences, Duke University School of Medicine, ^b Duke Clinical Research Institute, Duke University, ^c University of North Carolina Gillings School of Global Public Health, Department of Health Policy and Management, ^d Kaiser Permanente North California, Division of Research, ^e Department of Preventive Medicine and Public Health, University of Kansas Medical Center, ^f Department of Anesthesiology, University of Kansas Medical Center

Corresponding Author

Ruchir N. Karmali, PhD
Kaiser Permanente Northern California, Division of Research
2000 Broadway
Oakland, CA 94612
Phone: (510) 891-5595
Fax: (510) 891-3606
Email: Ruchir.N.Karmali@kp.org

Key Words: Analgesics, Opioid; chronic pain; Outcome Measurement Errors

Take Home Message:

1. Despite no gold standard definitions for long-term opioid therapy (LTOT), it is increasingly used as a component of quality improvement efforts to identify populations at risk for opioid-related adverse events and inform interventions to promote appropriate opioid therapy.
2. LTOT definitions often lacked information about dose and consistency of use, despite availability of these elements in secondary data sources.
3. Inconsistent definitions of LTOT have led to differences in estimates of the prevalence of LTOT and inconclusive evidence of the risk factors for LTOT.
4. Researchers should consider incorporating criteria that indicate consistency of opioid use when defining long-term opioid therapy perform sensitivity analyses to evaluate the robustness of LTOT measures.
5. A consensus about LTOT definitions is needed to identify patients with LTOT, understand the risk factors that lead to LTOT, and evaluate of clinical practices and policies aimed at reducing risky LTOT.

Word Count: 3,483
This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/pds.4929](https://doi.org/10.1002/pds.4929)

1 **Funding Disclosure:** RK was supported by the Kaiser Permanente Medical Group through the
2 Delivery Science Post-Doctoral Fellowship. SR received research funds from GSK for work
3 outside of the current work. AWR was supported by a CTSA grant from NCATS awarded to the
4 University of Kansas for Frontiers: University of Kansas Clinical and Translational Science
5 Institute (#KL2TR002367). CIC has received support through her institution from the Industry
6 PMR Consortium, a consortium of companies working together to conduct postmarketing studies
7 required by the Food and Drug Administration that assess known risks related to opioid analgesic
8 use. All authors did not receive any funding for this work.
9

Abstract

Purpose

This review sought to 1) describe definitions of long-term opioid therapy (LTOT) outcome measures, and 2) identify the predictors associated with the transition from short-term opioid use to LTOT for opioid-naïve individuals.

Methods

We conducted a systematic review of the peer-reviewed literature (1/2007-7/2018). We included studies examining opioid use for >30 days. We classified operationalization of LTOT based criteria used in the definitions. We extracted LTOT predictors from multivariate models in studies of opioid-naïve individuals.

Results

The search retrieved 5,221 studies, and 34 studies were included. We extracted 41 unique variations of LTOT definitions. About 36% of definitions required a cumulative duration of opioid use of 3 months. Only 17% of definitions considered consecutive observation periods, 27% used days' supply, and no definitions considered dose.

We extracted 76 unique predictors of LTOT from seven studies of opioid-naïve patients. Common predictors included pre-existing comorbidities (21.1%), non-opioid prescription medication use (13.2%), substance use disorders (10.5%), and mental health disorders (10.5%).

Conclusions

Most LTOT definitions aligned with the chronic pain definition (pain >3 months), and used cumulative duration of opioid use as a criterion, although most did not account for consistent use. Definitions were varied and rarely accounted for prescription characteristics, such as days' supply. Predictors of LTOT were similar to known risk factors of opioid abuse, misuse, and overdose. As LTOT becomes a central component of quality improvement efforts,

- 1 researchers should incorporate criteria to identify consistent opioid use to build the evidence for
- 2 safe and appropriate use of prescription opioids.

3

Introduction

For the nearly 20% of Americans and Canadians suffering from chronic non-cancer pain (CNCP), pain that lasts >3 months, prescription opioids are commonly used to relieve pain.¹⁻³ Although prescription opioids may be appropriate for short-term pain relief, long-term opioid therapy (LTOT) is not associated with improvements in pain or function.^{4,5} LTOT can lead to tolerance and escalating doses, and is associated with greater risk of opioid-related overdose and mortality.⁶ Across populations and healthcare settings, the rising prevalence of LTOT has paralleled increases with opioid-related overdose and mortality rates.⁷⁻¹³ Previous studies, which defined LTOT as opioid use >90 days, found that the prevalence of LTOT was 5.4% in the United States and 17% in Canada.^{11,14}

Defining LTOT is critical to understanding the risk factors that lead to LTOT and the evaluation of clinical practices and policies aimed at reducing risky opioid use that may occur with LTOT (e.g. high doses, concurrent benzodiazepine prescriptions, or other forms of opioid use that are associated with behaviors related to abuse, misuse, and addiction).¹⁵ The concept of LTOT has become a central component to assess quality of care. In 2018, the National Committee for Quality Assurance added “Risk of Continued Opioid Use” as a quality of care measure.¹⁶ The Centers for Disease Control and Prevention’s (CDC) guide to monitor quality of the implementation of the 2016 Guideline for Prescribing Opioids for Chronic Pain defines nine measures corresponding to different types of risky LTOT.^{17,18}

Adapted from the 2008 seminal observational study by Von Korff and colleagues on LTOT, clinical guidelines define LTOT as “use of opioids on most days for >3 months.”¹⁸⁻²¹ Yet, in research and clinical practice, the criteria used to define LTOT vary. Similar to other measures of medication use (e.g. adherence, persistence, compliance), researchers seeking to define LTOT

1 need to select cutoffs for the duration of medication use, length of time for follow-up, frequency
2 of fills, quantity, and days' supply to define LTOT.²²⁻²⁴ Previous systematic reviews of pain
3 medication use (covering studies published before 2014) for CNCP, examined constructs relating
4 to adherence such as overuse, underuse, and misuse of opioid and non-opioid medications, but
5 did not specifically examine LTOT.^{25,26} Reviews also examined predictors of opioid misuse and
6 abuse, and overdose, but predictors may differ for LTOT.²⁷⁻³²

7 Little is known about the criteria used to define LTOT for research purposes, and there
8 has been no synthesis of the risk factors associated with transition from short-term opioid therapy
9 to LTOT. Without an understanding of the criteria or the predictors of LTOT, it is difficult to
10 understand the strengths and limitations regarding the evidence on the risk of LTOT, distinguish
11 between episodic and long term opioid use, and monitor the prevalence and incidence of LTOT.
12 The purpose of this systematic review is to 1) document the varied definitions of LTOT used as
13 an outcome in observational research and 2) identify the risk factors associated with transition
14 from short-term opioid therapy to LTOT.

15 **Methods**

16 *Database and Search Strategy*

17 We systematically reviewed the peer-reviewed literature to identify empirical studies
18 investigating LTOT as an outcome following an indication for pain or initiation of prescription
19 opioid therapy. We searched Pubmed, Medline, and Scopus databases for peer-reviewed articles
20 published from January 2007 to July 2018. We chose this time period because the Food and
21 Drug Administration received additional authority for post-approval monitoring in 2007, and
22 there was there was specific attention to LTOT as demonstrated by the publication of clinical
23 guidelines and recognition that LTOT was an important clinical outcome of prescribed opioid

1 use for patients with CNCP during this time period.^{20,21,33} We worked with a research librarian to
2 develop a search strategy based on synonyms for three concepts: opioids, long-term opioid
3 therapy, and risk factors (Appendix 1).

4 *Study Selection*

5 We considered LTOT definitions that examined prescription opioid therapy over ≥ 30
6 days of calendar time follow-up. We did not require specific study designs but required studies to
7 measure LTOT as an outcome to understand the methodology used to define LTOT. To extract
8 the predictors of LTOT, the study had to compare LTOT to short-term opioid therapy either by
9 including a comparison group or examining opioid therapy over time to capture the shift from
10 short-term to LTOT and have LTOT as an outcome. Articles were excluded if they were not
11 written in English or were not original research. We also excluded studies not conducted in
12 United States or Canada to focus on countries with similar population characteristics and trends
13 in opioid use.^{13,34} We excluded studies where the outcome was chronic pain but not LTOT.
14 Studies with pediatric or cancer patients were excluded because guidelines for LTOT may differ
15 for these populations compared to patients with chronic non-cancer pain.^{18,19} Within included
16 studies, we identified a subset of studies with a new user study design to examine transitions to
17 LTOT from opioid-naïve state, defined using a washout period, or the period of time before the
18 index date without any opioid use.³⁵ Two authors screened each study based on the title, abstract,
19 and full text. We had group discussions to resolve conflicts and reach consensus for inclusion.

20 *Data Extraction*

21 For each included study, we extracted information about the sample (size,
22 characteristics), data source, comparison group, and LTOT prevalence. We indicated whether
23 studies applied a new user study design. If studies did not use a new user study design, we

1 examined how opioid use was assessed during the lookback period, or time period before the
2 index date.

3 We identified distinct definitions of LTOT used in each study and deconstructed the
4 components of each definition, which may capture the:

- 5 • type of event used to identify the index date for assessing LTOT
- 6 • follow-up time: calendar time observed after the index date
- 7 • start the measurement of LTOT: time points after the index date to collect
8 information for LTOT definition
- 9 • cumulative duration of opioid use: total amount of calendar time used to define LTOT
- 10 • use of multiple, distinct observation periods
- 11 • use of consecutive observation periods
- 12 • number of prescriptions
- 13 • days' supply: total number of days covered by a prescription
- 14 • gaps or overlaps between prescriptions

15 The CDC guideline indicates that the risk of opioid use increases with dose.¹⁸ Therefore,
16 we examine whether LTOT definitions use dose, reported in morphine milligrams equivalent.

17 We also examined whether definitions identified specific opioid types (e.g., oxycodone,
18 hydrocodone, long-acting etc.). Both dose and opioid type may be used to distinguish between
19 high and low risk LTOT.

20 Two authors independently identified study and definition characteristics and conflicts
21 were resolved by group discussion. Since many studies had more than one definition, we present
22 the percentage of definitions with each criterion.

1 Among the subset of studies with a new user study design, we identify the predictors
2 associated with the transition from short-term opioid therapy to LTOT from multivariate models.
3 We classified predictors according to the conceptual framework developed by Hooten and
4 colleagues to understand the gaps in evidence on the predictors of LTOT.³⁶ Predictors were
5 grouped into three domains: patient characteristics, practice characteristics, and prescriber
6 characteristics.³⁶ Within each domain, we grouped similar predictors into categories. We
7 describe the number of times a predictor was used across the models, whether odds ratio for each
8 predictor was <1, >1, not significant, or not reported.

9 **Results**

10 The search retrieved 5,221 studies (Figure 1). After removing duplicates, we reviewed
11 3,555 studies and selected 183 studies for full text review. Thirty-four studies were included for
12 data extraction (Table 1).

13 Over 75% (n=27) of the studies examined LTOT among patients who underwent surgery,
14 and 25% (n=7) examined LTOT among patients with CNCP. Seven studies had a new user study
15 design. Data sources included administrative claims data (N=20), medical records (N=13), and
16 survey data (N= 3).

17 *Characteristics of LTOT Definitions*

18 We extracted 41 unique variations of definitions of LTOT outcome measures (Table 2).
19 Common definitions of the index date included the surgery date (71% of definitions), the first
20 opioid prescription (10%), and the first visit (10%). Follow-up times for studies varied from 3.5
21 months to three years, and the most common follow-up time was one year (44%). Most
22 definitions had at least one measurement on the index date (51%), and 37% of definitions had at

1 least one measurement at three months after the index date. Cumulative duration of opioid use to
2 define LTOT varied from six weeks to one year, and most definitions used three months (46%).

3 Almost 30% of the definitions required more than one distinct observation period during
4 study follow-up. For example, one definition used two observation periods: between 30 days
5 before surgery and two weeks after the surgery and three to six months after surgery.³⁷ Only 17%
6 of definitions explicitly specified consecutive observation periods. For example, one definition
7 required a prescription fill for four consecutive 90-day time periods in the follow-up year.³⁸

8 The number of prescriptions required for LTOT varied from ≥ 1 (61%) to ≥ 12 (2%).
9 Days' supply was used for 27% of the definitions, and 90 days' supply was the most common
10 cutoff (12%). No definitions considered dose and 68% of definitions considered product type.
11 Only 7% of definitions accounted for the possibility of overlapping prescriptions. For 10% of the
12 definitions, LTOT was self-reported from patient surveys.

13 About 64% of the definitions specified opioid use in the lookback period. The length of
14 time used for the lookback period varied from three months (17%) to one year (22%), and most
15 definitions had a 1-year lookback period.

16 Only 24% of definitions specified a washout period for opioid use, or time without opioid
17 use before the index date. The amount of time for the washout period varied from three months
18 (7%) to three years (5%), and most definitions had a three-month washout period (7%).

19 *Prevalence of LTOT*

20 Estimates of LTOT prevalence varied across studies by population studied and LTOT
21 definition used (Table 1). For studies involving opioid-naïve patients with surgery (n=3), the
22 prevalence of LTOT during study follow-up ranged from 5.3% to 13%.^{37,39} The prevalence of
23 LTOT among studies of opioid-naïve patients (n=4) with chronic non-cancer pain ranged from

1 1.3% to 25%.^{40,41} Two studies did not provide enough information to calculate the LTOT
2 prevalence.^{42,43}

3 *Predictors of LTOT*

4 For the 7 studies with opioid-naïve individuals, we identified 76 unique possible
5 predictors of LTOT across eight analytic models that examined LTOT as an outcome (Table 3).
6 According to the domains of the conceptual framework by Hooten and colleagues for LTOT, all
7 predictors were classified as patient characteristics, and none of the predictors captured the
8 practice environment or prescriber characteristics.³⁶ Within the patient characteristics domains,
9 44.7% of predictors were classified as medical and mental health conditions, 19.7% were
10 sociodemographic factors, and 11.8% were pain etiology. There were no predictors that assessed
11 individual responses to pain and opioids. Although not included in the conceptual framework,
12 23% of the predictors referred to prior or baseline health service and medication use.³⁶

13 The most common predictors included age (eight models), sex (eight models), opioid
14 dose at baseline (four models), arthritis (four models), Black race (four models), and presence of
15 chronic pain (four models). Arthritis, chronic pain, tobacco use, drug disorders, and mental
16 health disorders were consistently associated with greater risk of LTOT.

17 **Discussion**

18 The systematic review identified 41 unique variations of definitions of LTOT across 34
19 studies. The definition of LTOT differed by the follow-up time, cumulative duration of opioid
20 use for LTOT, the time points used to define LTOT, and consistency of opioid use. All studies
21 included follow-up time of at least 3 months, but half of the definitions had follow-up times that
22 were <1 year. Shorter follow-up times make it difficult to observe LTOT that is defined as longer
23 than three months. For example, LTOT that begins near the end of a follow-up period would be

1 misclassified as short-term opioid therapy. Longer follow-up times would improve LTOT
2 identification and distinguish LTOT from episodic opioid therapy.

3 Most definitions used >3 months as the cumulative duration of opioid use for LTOT,
4 which aligns with guideline definitions of chronic pain.^{3,18,19} However, the length of time
5 required for LTOT does not always account for consistent opioid therapy during follow-up. The
6 definitions of opioid therapy during the time windows within the follow-up time were not strict
7 and many definitions only required one opioid prescription during a pre-defined time period for
8 LTOT.^{40,43-54} For example, one study defined LTOT as at least one prescription 305 to 425 days
9 after a hospital discharge.⁴⁴

10 By only requiring one prescription during a specified window of time after the index
11 date, these definitions fail to identify consistent use. Studies often used EHR data or claims data
12 which contain rich information about prescriptions, but LTOT definitions rarely incorporated
13 prescription characteristics such as the frequency of fills, fill dates, and days' supply. These
14 characteristics capture consistent opioid use and overlapping prescriptions which exemplify
15 differing levels of risky LTOT.¹⁸ Eleven definitions used days' supply, and only three definitions
16 used daily use to identify LTOT, a stark contrast to traditional measures of adherence which
17 often require days' supply in the definition.²³ Only three definitions described methods used to
18 account for gaps between prescriptions and overlapping prescriptions.^{39,41} Identifying consistent
19 use is important because it more closely reflects actual opioid therapy characteristics, compared
20 to fills at various time points during follow-up.

21 While length of time of opioid therapy is the only necessary criterion to define LTOT,
22 context about the nature of LTOT is important to identify patients who at highest risk for adverse
23 outcomes. According to clinical guidelines, dose and opioid type are associated with greater risk

of adverse events.¹⁸ None of the included studies used dose, and 68% of definitions distinguished opioid type in the definition of LTOT. Patients with LTOT may become tolerant or increase doses over time.¹⁸ Similarly, patients may also switch between long and short acting opioids during opioid use. Although technically reflective of LTOT, measures that do not account for these characteristics may not identify high-risk populations.²⁷ For example, identifying patients with doses above recommended thresholds (>90 MME) during LTOT allows providers to identify patients who could benefit from tapering opioid doses.¹⁸

Assessing clinical appropriateness of LTOT is challenging because definitions lacked clinical information (e.g. pain scores or functional status). Clinical information may not be available or easily accessible in claims or EHR data. Both claims and EHR data provide “as-prescribed” information, but they do not include patient behaviors (whether and how medications are consumed, disposed of, or diverted). For example, claims data only has data on prescriptions reimbursed by insurers, and does not have data on medications that were prescribed and never filled, or prescriptions that were paid for out-of-pocket or by other insurers. EHRs may not contain information about all medications dispensed. Without data on clinical indicators and all opioid prescriptions, clinically appropriate LTOT is difficult to distinguish from risky LTOT.

Very few LTOT definitions were described and implemented in exactly the same way. Von Korff and colleagues’ definition of LTOT was cited by several included studies.²⁰ LTOT was defined as “>90 days and >10 opioid prescriptions or >120 days’ supply” during a six-month follow-up time.²⁰ The definition also incorporated average daily doses by delineating between high-doses (>20 milligrams morphine equivalent) and low doses (<20 milligrams morphine equivalent).²⁰ The application of these definitions in the included studies was not always clear. Interestingly, one study took a data-driven approach for LTOT definitions by using group-based

1 trajectory modeling which identifies types of opioid use depending on changes in opioid use over
2 time.⁵⁵⁻⁵⁷ Data-driven approaches may improve the classification of LTOT, but studies have not
3 compared the performance of data-driven approaches to a simple, binary measures defined at
4 pre-specified time points. These definitions have not been validated with patient self-reports or
5 monitoring with urine drug screens.

6 Only a handful of included studies used prescription characteristics to define LTOT,
7 potentially reflecting a lack of guidance on using prescription characteristics, limited analytic
8 resources, or belief that prescriptions characteristics do not improve the sensitivity of the
9 measure. Existing guidance for researchers and health systems contains conflicting definitions
10 for LTOT.^{16-18,58,59} As illustrated in one study using prescription registry data to create different
11 LTOT definitions based on the dose, number of prescriptions, consistency of use, population
12 characteristics vary depending on the criteria used.⁶⁰ Inconsistent definitions of LTOT inhibit our
13 understanding of the utility of LTOT as an indicator of high-risk opioid use. We found that
14 application of the various definitions has led to highly variable estimates of the prevalence of
15 LTOT and inconclusive evidence on the risk factors of LTOT.

16 Across the studies of opioid-naïve individuals, the evidence regarding the predictors
17 associated with LTOT is limited to patient characteristics, reflecting the data elements available
18 in administrative data. The lack of evidence about individual responses to pain and opioid use as
19 well as the patient's preferences, knowledge, beliefs, and psychosocial stressors indicates a
20 limited self-reported data available from opioid naïve patients who develop LTOT. There was no
21 evidence about prescriber characteristics (e.g. pain management training, beliefs about opioid
22 prescriptions, and professionalism) and the practice environment (e.g. healthcare team
23 composition, capacity to deliver care, incentives, guideline adoption, prescribing laws, and

1 prescription drug monitoring use) in the included studies. Further research is needed to
2 understand how patient characteristics, prescriber characteristics, and practice environment
3 characteristics interact with one another to influence LTOT.

4 The most common predictors used in studies include age, sex, opioid dose at baseline,
5 and race, but the direction of the association varied depending on the model. However, in these
6 studies, arthritis, chronic pain, tobacco use, drug disorders, and mental health disorders were
7 consistently identified as risk factors for LTOT, many of which are similar to the risk factors
8 associated with misuse, abuse, and overdose.²⁷⁻³² Finally, only three predictors examined prior
9 opioid prescriptions, suggesting limited evidence on how initial prescribing may lead to LTOT.
10 In a study not included in this review because it included pediatric patients, the number of fills
11 and total dose during the first month of opioid use were associated with greater risk of LTOT.⁶¹

12 This review has several limitations. Our focus on the transition from short-term to LTOT
13 means we did not examine studies of the time to opioid discontinuation. We also excluded
14 studies where LTOT definitions were used solely to identify populations to target for
15 interventions or where LTOT was a predictor. A meta-analysis of the predictors of LTOT was
16 not feasible due to heterogeneity in study design and populations across the studies. Comparing
17 findings for predictors across studies may be difficult because of the variation in the LTOT
18 definition. Finally, we excluded studies that were published prior to 2007, which may have
19 resulted in the exclusion of additional definitions of LTOT. The evidence from this review is
20 limited to only the definitions of LTOT and does not assess how these definitions may impact the
21 estimates for the risk of adverse events associated with LTOT. The above limitations are unlikely
22 to alter our overall findings that the heterogeneity in study designs, populations, and LTOT
23 definitions prevent the meta-analysis and comparison of predictors of LTOT across studies.

1 The implications of measurement error and misclassification, particularly for opioid
2 research using large administrative datasets, are not unique to defining LTOT, and have been
3 discussed in reviews of other measures such as opioid abuse and nonmedical prescription opioid
4 use.^{30,62,63} This study does not identify a common length of time for LTOT, nor did it aim to
5 address the appropriate cutoff for the length of time used to define LTOT. At a minimum,
6 researchers should include criteria that reflect consistent opioid use over time. Validation of
7 LTOT definitions can better support efforts to predict and prevent LTOT. Researchers should
8 consider incorporating clinical information available from data sources, such as patient-reported
9 outcome measures (e.g. pain, functioning) or EHR data, to better distinguish between clinically
10 appropriate and inappropriate LTOT as well as low-risk and high-risk LTOT. Incorporating
11 opioid dose exposure into LTOT definitions can distinguish the risks associated with LTOT.
12 Patient reported measures and opioid dose can create risk-stratified definitions of LTOT to
13 inform the selection of interventions for LTOT based on risk. Diverse data sources, including
14 primary collection, could identify multi-level risk factors that influence LTOT. Researchers
15 should perform sensitivity analyses around their selected definition of LTOT to evaluate the
16 robustness of their measure. Applying these recommendations will reduce bias and improve the
17 internal validity of studies that examine LTOT as an outcome.⁶³

18 **Conclusion**

19 LTOT is quickly becoming a component used to assess quality of care for CNCP
20 patients. We found that across studies of CNCP patients from the last decade, definitions of
21 LTOT have been inconsistent, often lacking key prescription characteristics, such as opioid
22 product type (e.g. long acting vs short acting), frequency of fills, dose, and days' supply, that
23 could distinguish between low and high-risk LTOT. Use of unstandardized LTOT definitions

1 have led to inconsistent estimates of the prevalence of LTOT and weak evidence on the risk
2 factors of LTOT. Without addressing the potential bias resulting from misclassification and
3 measurement error of LTOT measures, translating findings into policies and clinical practices to
4 prevent adverse events that stem from LTOT will be difficult.

5 **Acknowledgements**

6 SRR received research funds from GSK for work outside of the current work. AWR was
7 supported by a CTSA grant from NCATS awarded to the University of Kansas for Frontiers:
8 University of Kansas Clinical and Translational Science Institute (#KL2TR002367). CIC has
9 received support through her institution from the Industry PMR Consortium, a consortium of
10 companies working together to conduct postmarketing studies required by the Food and Drug
11 Administration that assess known risks related to opioid analgesic use. All authors did not
12 receive any funding for this work.

References

1. Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. *Morbidity and Mortality Weekly Report*. 2018;67(36):1001.
2. Schopflocher D, Taenzer P, Jovey R. The prevalence of chronic pain in Canada. *Pain research and management*. 2011;16(6):445-450.
3. International Association for the Study of Pain. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. *Pain Suppl*. 1986(3):S1–226.
4. Abdel Shaheed C, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain: A Systematic Review and Meta-analysis. *JAMA Intern Med*. 2016;176(7):958-968.
5. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016.
6. Baldini A, Von Korff M, Lin EH. A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's Guide. *Prim Care Companion CNS Disord*. 2012;14(3).
7. Campbell CI, Weisner C, Leresche L, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. *Am J Public Health*. 2010;100(12):2541-2547.
8. Kuo YF, Raji MA, Chen NW, Hasan H, Goodwin JS. Trends in Opioid Prescriptions Among Part D Medicare Recipients From 2007 to 2012. *The American journal of medicine*. 2016;129(2):221.e221-230.
9. Axeen S. Trends in Opioid Use and Prescribing in Medicare, 2006–2012. *Health Serv Res*. 2018;Oct;53(5):3309-3328.
10. Smolina K, Gladstone EJ, Rutherford K, Morgan SG. Patterns and trends in long-term opioid use for non-cancer pain in British Columbia, 2005–2012. *Canadian Journal of Public Health*. 2016;107(4-5):e404-e409.
11. Mojtabai R. National trends in long-term use of prescription opioids. *Pharmacoepidemiology and drug safety*. 2018;27(5):526-534.
12. Sullivan MD, Edlund MJ, Fan M-Y, DeVries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. *Pain*. 2008;138(2):440-449.
13. Centers for Disease Control and Prevention. Annual Surveillance Report of Drug-Related Risks and Outcomes — United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. Accessed 3/2/2019 from <https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf>. 2018.
14. Canadian Institute for Health Information. Pan-Canadian Trends in the Prescribing of Opioids, 2012 to 2016. Ottawa, ON: CIHI; 2017.
15. Von Korff MR. Long-term use of opioids for complex chronic pain. *Best Pract Res Clin Rheumatol*. 2013;27(5):663-672.
16. HEDIS. NCQA Updates Quality Measures for HEDIS® 2019. 2018; <https://www.ncqa.org/news/ncqa-updates-quality-measures-for-hedis-2019/>. Accessed April 1, 2019.
17. Centers for Disease Control and Prevention. *Quality Improvement and Care Coordination: Implementing the CDC Guideline for Prescribing Opioids for Chronic Pain 2018 National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention, Atlanta, GA*
18. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. *MMWR Recomm Rep*. 2016;65(1).

19. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. *Canadian Medical Association Journal*. 2017;189(18):E659-E666.
20. Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. *Clin J Pain*. 2008;24(6):521-527.
21. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *The Journal of Pain*. 2009;10(2):113-130. e122.
22. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. *Pharmacoepidemiol Drug Saf*. 2006;15(8):565-574; discussion 575-567.
23. Lam WY, Fresco P. Medication Adherence Measures: An Overview. *BioMed research international*. 2015;2015:217047.
24. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2008;11(1):44-47.
25. Timmerman L, Stronks D, Groeneweg J, Huygen F. Prevalence and determinants of medication non-adherence in chronic pain patients: a systematic review. *Acta Anaesthesiologica Scandinavica*. 2016;60(4):416-431.
26. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: Is there a problem? *European Journal of Pain*. 2009;13(2):115-123.
27. Park TW, Lin LA, Hosanagar A, Kogowski A, Paige K, Bohnert AS. Understanding Risk Factors for Opioid Overdose in Clinical Populations to Inform Treatment and Policy. *J Addict Med*. 2016;Nov/Dec(10):6.
28. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. *Clin J Pain*. 2008;24(6):497-508.
29. Sehgal N, Manchikanti L, Smith HS. Prescription Opioid Abuse in Chronic Pain: A Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse. *Pain Physician*. 2012;15.
30. Alzeer AH, Jones J, Bair MJ. Review of factors, methods, and outcome definition in designing opioid abuse predictive models. *Pain Med*. 2017;19(5):997-1009.
31. Kaye AD, Jones MR, Kaye AM, et al. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1. *Pain Physician*. 2017;20(2S):S93-S109.
32. Kaye AD, Jones MR, Kaye AM, et al. Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2). *Pain Physician*. 2017;20(2S):S111-S133.
33. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. *Pain*. 1994;59(2):201-208.
34. Canadian Institute for Health Information. Pan-Canadian Trends in the Prescribing of Opioids and Benzodiazepines, 2012 to 2017. Ottawa, ON: CIHI; 2018.
35. Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. *Pharmacoepidemiology and drug safety*. 2013;22(1):1-6.
36. Hooten WM, Brummett CM, Sullivan MD, et al. A Conceptual Framework for Understanding Unintended Prolonged Opioid Use. *Mayo Clinic proceedings*. 2017;92(12):1822-1830.
37. Johnson SP, Chung KC, Zhong L, et al. Risk of Prolonged Opioid Use Among Opioid-Naive Patients Following Common Hand Surgery Procedures. *The Journal of hand surgery*. 2016;41(10):947-957.e943.

38. Franklin GM, Rahman EA, Turner JA, Daniell WE, Fulton-Kehoe D. Opioid use for chronic low back pain: A prospective, population-based study among injured workers in Washington state, 2002-2005. *The Clinical journal of pain*. 2009;25(9):743-751.
39. Mosher HJ, Hofmeyer BA, Hadlandsmyth K, Richardson KK, Lund BC. Predictors of long-term opioid use after opioid initiation at discharge from medical and surgical hospitalizations. *Journal of hospital medicine*. 2018;13(4):243-248.
40. Thornton JD, Dwibedi N, Scott V, et al. Predictors of Transitioning to Incident Chronic Opioid Therapy Among WorkingAge Adults in the United States. *Am Health Drug Benefits*. 2018;11(1):12-21.
41. Ray GT, Bahorik AL, VanVeldhuisen PC, Weisner CM, Rubinstein AL, Campbell CI. Prescription opioid registry protocol in an integrated health system. *Am J Managed Care*. 2017;23(5):e146-e155.
42. Sun EC, Bateman BT, Memtsoudis SG, Neuman MD, Mariano ER, Baker LC. Lack of Association Between the Use of Nerve Blockade and the Risk of Postoperative Chronic Opioid Use Among Patients Undergoing Total Knee Arthroplasty: Evidence From the Marketscan Database. *Anesth Analg*. 2017;125(3):999-1007.
43. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. *Pain*. 2016;157(6):1259-1265.
44. Daoust R, Paquet J, Moore L, et al. Incidence and Risk Factors of Long-term Opioid Use in Elderly Trauma Patients. *Ann Surg*. 2018;268(6):985-991.
45. Holman JE, Stoddard GJ, Higgins TF. Rates of prescription opiate use before and after injury in patients with orthopaedic trauma and the risk factors for prolonged opiate use. *The Journal of bone and joint surgery American volume*. 2013;95(12):1075-1080.
46. Jiang X, Orton M, Feng R, et al. Chronic Opioid Usage in Surgical Patients in a Large Academic Center. *Ann Surg*. 2017;265(4):722-727.
47. Rosenbloom BN, McCartney CJL, Canzian S, Kreder HJ, Katz J. Predictors of Prescription Opioid Use 4 Months After Traumatic Musculoskeletal Injury and Corrective Surgery: A Prospective Study. *J Pain*. 2017;18(8):956-963.
48. Anciano Granadillo V, Cancienne JM, Gwathmey FW, Werner BC. Perioperative Opioid Analgesics and Hip Arthroscopy: Trends, Risk Factors for Prolonged Use, and Complications. *Arthroscopy*. 2018;34(8):2359-2367.
49. Cancienne JM, Patel KJ, Browne JA, Werner BC. Narcotic Use and Total Knee Arthroplasty. *J Arthroplasty*. 2018;33(1):113-118.
50. Mueller KG, Memtsoudis SG, Mariano ER, Baker LC, Mackey S, Sun EC. Lack of Association Between the Use of Nerve Blockade and the Risk of Persistent Opioid Use Among Patients Undergoing Shoulder Arthroplasty: Evidence From the Marketscan Database. *Anesth Analg*. 2017;125(3):1014-1020.
51. Pugely AJ, Bedard NA, Kalakoti P, et al. Opioid use following cervical spine surgery: trends and factors associated with long-term use. *Spine J*. 2018.
52. Qureshi R, Werner B, Puvanesarajah V, et al. Factors Affecting Long-Term Postoperative Narcotic Use in Discectomy Patients. *World Neurosurg*. 2018;112:e640-e644.
53. Bartels K, Fernandez-Bustamante A, McWilliams SK, Hopfer CJ, Mikulich-Gilbertson SK. Long-term opioid use after inpatient surgery - A retrospective cohort study. *Drug Alcohol Depend*. 2018;187:61-65.
54. Rozet I, Nishio I, Robbertze R, Rotter D, Chansky H, Hernandez AV. Prolonged opioid use after knee arthroscopy in military veterans. *Anesthesia and analgesia*. 2014;119(2):454-459.
55. Kim SC, Choudhry N, Franklin JM, et al. Patterns and predictors of persistent opioid use following hip or knee arthroplasty. *Osteoarthritis Cartilage*. 2017;25(9):1399-1406.

- 1 56. Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: a new approach to
2 classifying and predicting long-term medication adherence. *Medical care*. 2013;51(9):789-796.
- 3 57. Jones BL, Nagin DS. Advances in Group-Based Trajectory Modeling and an SAS Procedure for
4 Estimating Them. *Sociological Methods & Research*. 2007;35(4):542-571.
- 5 58. U.S. Department of Health & Human Services, Office of Inspector General. Using Data Analysis
6 To Calculate Opioid Levels and Identify Patients At Risk of Misuse or Overdose.(Report No. OEI-
7 02-17-005600). retrieved from <https://oig.hhs.gov/oei/reports/oei-02-17-00560.pdf>. In.
8 Washington D.C. 2018.
- 9 59. Kaiser Foundation Health Plan of Washington. Patients on Chronic Opioid Therapy for Chronic
10 Non-Cancer Pain Safety Guideline. retrieved from
11 <https://wa.kaiserpermanente.org/static/pdf/public/guidelines/opioid.pdf>. In:2016.
- 12 60. Svendsen K, Skurtveit S, Romundstad P, Borchgrevink PC, Fredheim OM. Differential patterns of
13 opioid use: defining persistent opioid use in a prescription database. *Eur J Pain*. 2012;16(3):359-
14 369.
- 15 61. Deyo RA, Hallvik SE, Hildebran C, et al. Association Between Initial Opioid Prescribing Patterns
16 and Subsequent Long-Term Use Among Opioid-Naive Patients: A Statewide Retrospective
17 Cohort Study. *J Gen Intern Med*. 2017;32(1):21-27.
- 18 62. Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad WF. Defining Nonmedical
19 Use of Prescription Opioids Within Health Care Claims: A Systematic Review. *Subst Abus*.
20 2015;36(2):192-202.
- 21 63. Ranapurwala SI, Naumann RB, Austin AE, Dasgupta N, Marshall SW. Methodologic limitations of
22 prescription opioid safety research and recommendations for improving the evidence base.
23 *Pharmacoepidemiology and drug safety*. 2019;28(1):4-12.
- 24 64. Alghnam S, Castillo R. Traumatic injuries and persistent opioid use in the USA: findings from a
25 nationally representative survey. *Inj Prev*. 2017;23(2):87-92.
- 26 65. Anderson JT, Haas AR, Percy R, Woods ST, Ahn UM, Ahn NU. Chronic Opioid Therapy After
27 Lumbar Fusion Surgery for Degenerative Disc Disease in a Workers' Compensation Setting.
28 *Spine*. 2015;40(22):1775-1784.
- 29 66. Brummett CM, Waljee JF, Goesling J, et al. New Persistent Opioid Use After Minor and Major
30 Surgical Procedures in US Adults. *JAMA Surg*. 2017;152(6):e170504.
- 31 67. Connolly J, 3rd, Javed Z, Raji MA, Chan W, Kuo YF, Baillargeon J. Predictors of Long-term Opioid
32 Use Following Lumbar Fusion Surgery. *Spine (Phila Pa 1976)*. 2017;42(18):1405-1411.
- 33 68. Crocker JA, Yu H, Conaway M, Tuskey AG, Behm BW. Narcotic use and misuse in Crohn's disease.
34 *Inflammatory bowel diseases*. 2014;20(12):2234-2238.
- 35 69. Deyo RA, Hallvik SE, Hildebran C, et al. Use of prescription opioids before and after an operation
36 for chronic pain (lumbar fusion surgery). *Pain*. 2018;159(6):1147-1154.
- 37 70. Dunn LK, Yerra S, Fang S, et al. Incidence and Risk Factors for Chronic Postoperative Opioid Use
38 After Major Spine Surgery: A Cross-Sectional Study With Longitudinal Outcome. *Anesth Analg*.
39 2018;127(1):247-254.
- 40 71. Fritz JM, King JB, McAdams-Marx C. Associations Between Early Care Decisions and the Risk for
41 Long-term Opioid Use for Patients With Low Back Pain With a New Physician Consultation and
42 Initiation of Opioid Therapy. *Clin J Pain*. 2018;34(6):552-558.
- 43 72. Jain N, Brock JL, Phillips FM, Weaver T, Khan SN. Chronic preoperative opioid use is a risk factor
44 for increased complications, resource use, and costs after cervical fusion. *Spine J*. 2018.
- 45 73. Koeppe J, Lichtenstein K, Armon C, et al. Factors associated with initiation of prolonged
46 analgesic use among patients in the HIV Outpatient Study (HOPS). *The Clinical journal of pain*.
47 2011;27(8):699-706.

- 1 74. Kulshrestha S, Barrantes F, Samaniego M, Luan FL. Chronic opioid analgesic usage post-kidney
2 transplantation and clinical outcomes. *Clinical transplantation*. 2014;28(9):1041-1046.
- 3 75. Mulligan RP, McCarthy KJ, Gear BJ, Richardson DR, Ishikawa SN, Murphy GA. Psychosocial Risk
4 Factors for Postoperative Pain in Ankle and Hindfoot Reconstruction. *Foot & ankle international*.
5 2016;37(10):1065-1070.
- 6 76. Namba RS, Singh A, Paxton EW, Inacio MCS. Patient Factors Associated With Prolonged
7 Postoperative Opioid Use After Total Knee Arthroplasty. *J Arthroplasty*. 2018;33(8):2449-2454.
- 8 77. Raebel MA, Newcomer SR, Bayliss EA, et al. Chronic opioid use emerging after bariatric surgery.
9 *Pharmacoepidemiology and drug safety*. 2014;23(12):1247-1257.
- 10 78. Rozet I, Nishio I, Robbertze R, Rotter D, Chansky H, Hernandez AV. Prolonged opioid use after
11 knee arthroscopy in military veterans. *Anesthesia and analgesia*. 2014;119(2):454-459.
- 12 79. Rao AG, Chan PH, Prentice HA, et al. Risk factors for postoperative opioid use after elective
13 shoulder arthroplasty. *J Shoulder Elbow Surg*. 2018;27(11):1960-1968.
- 14
- 15
- 16

Table 1: Characteristics of included studies

Article	Study sample Description (N)	Source of Data for Long-term use measure	Definition Summary	Comparison Group	Percent Long-term users
1. Alghnam 2017 ⁶⁴	Adults (18+) (N=36,824)	Survey data (Medical Expenditure Panel Survey)	Self-reported opioid use in two of the final three rounds of the Medical Expenditure Panel Survey (totaling 8 months of time)	Patients without long-term use	15.60%
2. Anderson 2015 ⁶⁵	Workers' compensation recipients in Ohio who had lumbar fusion from 1993 to 2013 (N=1,002)	Administrative claims database (Ohio Bureau of Workers' Compensation)	Post-operative long-term use: starting six weeks after the surgery, more than 365 days' opioid supply in the 3-year follow-up period Pre-operative long-term use: 120 days' opioid supply in the year before surgery.	Less than 365 days' supply of opioids in the year following a 6-week post-operative period.	575/1002=57%
3. Bartels 2018 ⁵³	Patients with surgery during October 2011 and September 2013 (N=6,003)	Electronic health record (University of Colorado Hospital)	At least one opioid prescription fill 31 to 180 days after surgery	Patients without long-term prescription	43.6%
4. Brumett 2017 ⁶⁶	Opioid-naïve, US adults age 19 to 64 with a surgical procedure between 2013 and 2014 (N=36,177)	Administrative claims data (Clinformatics Data Mart)	At least one opioid prescription fill in each of two time periods: 30 days before through 14 days after surgery and 90-180 days after surgery	Patients without surgery, anesthesia, or an opioid prescription in a 12-month period	Minor surgery group: 5.9% Major surgery group: 6.5% Nonoperative control group: 0.4%
5. Cancienne 2018 ⁴⁹	patients who underwent primary total knee arthroplasty from 2007 to the first quarter of 2016 (N=113,337)	Administrative claims data (pearlriver patient records)	At least one opioid prescription fill 3 to 6 months after surgery.	patients without long-term use	35,770/113,337=32%

6. Connolly 2017 ⁶⁷	US adults with lumbar spinal fusion surgery during 2009 to 2012 (N=8,377)	Administrative claims data (Clinformatics Data Mart)	At least 365 days' supply in the 2-year follow-up period after surgery.	Patients without long-term opioid use	29.34%
7. Crocker 2014 ⁶⁸	Patients with Crohn's Disease and functional gastrointestinal disorder diagnosis from 2006 to 2011 (N=931)	Electronic medical record (University of Virginia Digestive Health Center) and the prescription monitoring program data base (Virginia and West Virginia)	One opioid prescription fill per month for 3 consecutive months in 12-month follow-up period or more than 2 prescription opioid fills in any 6-month period of the 12-month follow-up period.	Two groups- Crohn's Disease with and without functional gastrointestinal disorders	192/931=21%
8. Deyo 2018 ⁶⁹	patients with lumbar fusion from October 2012 to September 2013 (N=2,491)	Administrative data (Oregon prescription drug monitoring program)	Pre-operative long-term use was at least 4 opioid prescription fills in the 7 months before the index date where 3 fills occur within 180 days before the index date. Post-operative long-term use was at least 4 opioid prescription fills in 7 months after the index date with at least 3 prescriptions 30 days after the hospitalization	patients without postoperative long-term opioid use	12.8%
9. Daoust 2017 ⁴⁴	Canadian adults, age 65+, with a trauma admission from April 2004 to March 2014 (N=84,241)	Administrative database (Medical Consultations and Medication database in Quebec)	At least one opioid prescription fill 305 to 425 days after hospital discharge	Patients without opioid prescription 1 year after injury.	4,337/39,833=10.9%
10. Dunn 2018 ⁷⁰	Patients who received elective spinal fusion from March 2011 to February 2016 (N=1,477)	Electronic health record (University of Virginia)	Documented opioid use at each of the following postoperative time periods: 1-3 days, 1 month, 6, month, and 12 months	Patients without opioid use at 12 months	(67+498)/1477=38%

11. Franklin 2009³⁸	Workers with acute back injury at risk for long-term disability from 2002 to 2004 (N=1,296)	Administrative pharmacy claims data (Washington workers' compensation medical billing database)	At least one opioid prescription fill in each of 4 consecutive calendar quarters	patients with opioid use during fewer than 3 quarters	111/1,843= 6.02%
12. Goesling 2016⁴³	Patients with total knee arthroplasty and total hip arthroplasty from March 2010 to May 2013 (N=574)	medical records and confirmation with patient during follow-up (telephone surveys and validated questionnaires)	No explicit definition. Self-reported opioid use was assessed at 30 days, 90 days, and 180 days after surgery.	Patients without opioid use at 6 months	Not information to calculate rate
13. Fritz 2018⁷¹	Opioid naïve patients with low back pain from 2012 to 2014 (N=707)	Administrative data (University of Utah Health Plan)	More than 120 days' supply or more than 10 opioid prescription fills with more than 90 days' supply during 1-year follow-up.	Patients without long-term use	24.3%
14. Granadillo 2018⁴⁸	Patients with hip arthroscopy from 2007 to 2015 (N=1,708)	Administrative claims data (pearlriver patient records)	At least one opioid prescription fill 3 to 6 months after surgery.	Patients without long-term use	468/1708=27.4%
15. Holman 2013⁴⁵	Patients with orthopedic trauma from June 2005 to June 2007 (N=748)	Administrative data (Utah Controlled Substance Database)	No explicit definition. Presence of at least one opioid prescription fill was assessed during three time periods in the 6-month follow-up period after surgery: 0 to 6 weeks, 6 to 12 weeks, and more than 12 weeks.	Patients without continued use of opioids 6 weeks after surgery	LTOT prevalence for more than 12 weeks: 19.7%
16. Jain 2018⁷²	Patients with primary cervical fusion for degenerative pathology from 2007 to the third quarter of 2015 (N=29,101)	Administrative claims data (Pearl Diver Humana database)	Preoperative long-term use is at least one prescription during the following preoperative time periods: 0 to two weeks, 2 weeks to 1 month, 1-3 months, 3-6 months, and 6 months. Postoperative long-term use is at least one prescription during the following post-operative time periods: 0-6 weeks, 6 weeks to 3 months, 3-6 months, 6-9 months, and 9-12 months.	Patients without preoperative long-term use Patients without postoperative long-term use	49.2%

17. Jiang 2017⁴⁶	Adults who received surgical care from 2010 to 2011 (N=79,123)	Electronic medical record (University of Pennsylvania Health system)	At least 90 days of opioid use between the first and last recorded outpatient visit occurring within a 2-year observation period	patients without chronic opioid use	9.2%
18. Johnson 2016³⁷	Adults with elective and trauma related hand surgery procedures from 2010 to 2012 (N=77,573)	Administrative data (Truven Market-Scan Commercial Claims Research Database)	At least one opioid prescription fill in each of two time periods: 30 days before through 14 days after surgery and 90-180 days after surgery	Patients without long-term opioid use	Of the opioid naïve patients with a perioperative opioid prescription (N=59,735), 13%
19. Kim 2017⁵⁵	Patients with hip or knee arthroplasty from 2004 to 2013 (N=57,545)	Administrative data (United healthcare/optum Clinformatics Data Mart Database)	Monthly opioid use for 12 consecutive months	Patients without long-term opioid use	43,94/57,545=7.6%
20. Koeppe 2011⁷³	Opioid naïve, US Adults with HIV from 11 clinics from 1998 to 2008 (N=931)	Medical Records (data from the HIV Outpatient Study)	Measured prolonged analgesic use, defined as 90 or more consecutive days of opioid or nonopioid analgesic medication use.	Patients without long-term opioid use	931/4180=22%
21. Kulshrestha 2014⁷⁴	Adults who have kidney transplant from 2004 to 2008 (N=1,045)	Electronic medical record (single center study, name not reported)	1. Opioid use reported during three time periods after surgery: 1-2 months, 3-6 months, and 10 to 12 months. 2. Opioid use reported during the 1-2 month and 3-6 month follow-up period only if patient had a graft loss or died during the 3-12 month follow-up period	Patients without long-term opioid use	119/(119+926)=11%
22. Mosher 2018³⁹	Patients with an outpatient opioid prescription during FY 2011 that was preceded by a 1-year opioid-free period (N=43,027)	Administrative data (Veterans Health Administration)	More than 90 days of continuous opioid use (determined by the days' supply), with the initiation of the episode beginning within the first 30 days of the first prescription.	Patients without long-term use	Medicine: 15.2% Surgery: 5.3% Total sample: 9.10%

23. Mueller 2017⁵⁰	Patients with total shoulder arthroplasty and shoulder hemiarthroplasty during 2002 to 2012 (N=6,988)	Administrative claims data (Marketscan)	Preoperative long-term use was more than 10 opioid prescription fills or 120 days' opioid supply during the year before surgery. Postoperative long-term use was at least one prescription during the follow-up	Patients with and without nerve block	50.1% of patients without nerve block; 49.5% among patients with nerve block
24. Mulligan 2016⁷⁵	Patients with ankle or hindfoot reconstruction (N=132)	Electronic medical record (study site not reported)	Opioid prescription from 90 days to 2 years after surgery	Patients without continued use 90 days after surgery	35%
25. Namba 2018⁷⁶	Patients with unilateral primary total knee arthroplasty from 2008 to 2011 (N=23,726)	Electronic medical record (Kaiser Permanente Northern California, Southern California, and Hawaii)	No explicit definition. Assessed presence of opioid prescription during each quarter of the follow-up year after surgery.	Patients without an opioid prescription in that quarter (separate models for each quarter)	Days 1-90: 92.7% Days 91-180: 42.1% Days 181-270: 32.2% Days 271-360: 30.4%
26. Pugley 2018⁵¹	Patients with cervical spinal arthrodesis from 2007 to 2014 (N=17,391)	Administrative data (Humana Inc via PearlDiver)	One or more opioid prescription fill at 1 year after surgery.	Patients without opioid use in the 3 months before surgery	LTOT at 12 months: 27.6%
27. Qureshi 2018⁵²	Patients with discectomy from 2007 to 2015 (N=1,321)	Administrative data (PearlDiver)	Opioid prescription fill 3-6 months after surgery	Patients without long-term prescription	(621/621+700) = 47%
28. Raebel 2014⁷⁷	Adults (21+) with bariatric surgery without chronic opioid use before surgery from 9 health systems from 2005 to 2009 (N=10,643)	Electronic medical record (outpatient pharmacy dispensing data) (nine health systems participating in the Scalable Partnering Network (SPAN))	10 or more opioid prescription fills over more than 90 days, or more than 120 days' opioid supply during one year of follow-up More than 120 days' supply during the 1-year follow-up.	Patients without chronic opioid use the year after surgery	4%
29. Ray 2017⁴¹	Opioid naïve patients (+19) with at least 1 opioid prescription 2011 (N=2,480,030)	Electronic medical record (Kaiser Permanente Northern California)	At least 3 months of opioid use with either more than 120 days' opioid supply or 10 or more opioid prescription fills during 3-year follow-up period.	Cohort of patients without opioid fill in 2011	112,089/455,693=25%

30. Rosenbloom 2017⁴⁷	Adults with musculoskeletal surgery (n=122)	Patient reported survey (2 large level I trauma centers (Sunnybrook Health Sciences Centre [SHSC] and St. Michael's Hospital [SMH]), in Toronto, Canada)	Self-reported opioid use in the past week at 4 months after injury	Patients without opioid prescription at 4 months after surgery	35%
31. Rozet 2014⁷⁸	US veterans 18 to 50 with elective ambulatory knee arthroscopic surgery from 2007 to October 2010 (N=145)	Electronic medical record (Veterans Affairs' Tertiary Medical Center (Seattle Division, VA PSHCS))	At least 3 months of "uninterrupted" opioid use after surgery.	Patients with and without post-traumatic stress disorder	30%
32. Rao 2018⁷⁹	Patients with shoulder arthroplasty registry from 2008 to 2014 (N=4,243)	Shoulder Arthroplasty Registry which includes data collected from electronic intraoperative forms, electronic health records, administrative claims, membership data, and mortality records (Kaiser Permanente Hawaii, Northern California, and Southern California)	No explicit definition. Assessed presence of opioid prescription during each quarter of the follow-up year after surgery.	patients without an opioid prescription in that quarter (separate models for each quarter)	Opioid use in the rehabilitation period ranged from 38% to 42% though specific percentages are not reported.
33. Sun 2017⁴²	patients with total knee arthroplasty from 2002 to 2012 (N=120,080)	Administrative claims data (Marketscan)	More than 10 opioid prescription fills or 120 days' opioid supply 91-365 days post-surgery	Patients without long-term use	Unable to calculate LTOT

34. Thornton 2018⁴⁰	patients with and opioid prescription from 2007 to May 2015 (N=491,442)	Administrative Claims Data (IMS Health/Quintiles, IQVIA)	More than 90 days' supply during the 4 months follow up period	Patients without long term use	1.30%
---	--	---	---	-----------------------------------	-------

Table 2 Characteristics of definitions of long-term opioid use (n=41)

Index event for follow up		
Surgery	29	71%
First visit	4	10%
first prescription	4	10%
Hospital discharge	2	5%
acute injury	1	2%
14 days after hospitalization	1	2%
Unclear	2	5%
Study follow-up time		
3.5 months	1	2%
4 months	2	5%
6 months	10	24%
7 months	1	2%
1 year	18	44%
14 months	1	2%
2 years	3	7%
3 years	3	7%
Unclear	2	5%
Time points of measurement: time points used to collect information for LTOT definition.		
1 month before index date	1	2%
index date	21	51%
first visit with first prescription	1	2%
14 days after index date	1	2%
1 month after index date	6	15%
6 weeks after index date	3	7%
3 months after index date	15	37%
4 months after index date	2	5%
6 months after index date	5	12%
8 months after index date	1	2%
9 months after index date	3	7%
10 month after index date	1	2%
305 days after index date	1	2%
12 months after index date	4	10%
16 months after index date	1	2%
Cumulative duration of opioid use: total amount of calendar time used to define LTOT		
6 weeks	1	2%
3 months	19	46%
4 months	5	12%
5 months	1	2%
6 months	3	7%
7 months	2	5%
8 months	1	2%
9 months	2	5%
1 year	7	17%
Unclear	2	5%

Use of use of multiple, distinct observation periods (required more than 1, not including pre/post op)		
Yes	12	29%
No	29	71%
Consecutive time periods (explicitly states consecutive)		
Yes	7	17%
Daily	3	7%
Monthly	2	5%
Quarterly	1	2%
Other	1	2%
no/not explicitly stated in the definition	34	83%
Number of prescriptions		
at least 1	25	61%
at least 2	6	15%
at least 3	2	5%
at least 4	3	7%
at least 5	1	2%
at least 10	4	10%
at least 12	1	2%
Used days supply		
Yes	11	27%
≥ 90 days supply	5	12%
≥ 120 days supply	4	10%
≥ 365 days supply	2	5%
No	30	73%
Accounts for overlapping prescription		
Yes	3	7%
No	38	93%
Used Dose		
Yes	0	0%
No	41	100%
Identified opioid product type		
Yes	28	68%
No	13	32%
Long-term use is self-reported (from patient surveys)		
Yes	4	10%
No	37	90%
Type of data used		
administrative data	39	95%
survey data	4	10%
Washout period (and length of time required without opioid use)		
Yes	10	24%
3 months before the index	3	7%
11 months preceding the month before surgery	2	5%
12 months before index	2	5%
3 years before index	2	5%

Unclear	1	2%
No	31	76%

Opioid use in look back period (and length of time required for look back period to detect opioid use)

Yes	26	63%
3 months	7	17%
4 months	3	7%
6 months	1	2%
>250 days	1	2%
1 year	9	22%
unclear time period	5	12%
No	15	37%

Table 3: Predictors of long-term opioid therapy

Category	Variable	Interpretation	Number of time odds reported greater than 1	Number of time odds reported less than 1	Number of time odds reported equal to 1	Number of models	References
Demographics	Age	Older age; lower risk (measured as categorical variable)	5	4	4	8	37,39-41,64,66,71
Demographics	Sex	Females have greater risk	2	3	3	8	37,39-41,64,66,71
Opioid use	Opioid dose	greater dose, greater risk	1	3	2	4	39,40,66
Pain diagnosis	Arthritis	Presence of arthritis, greater risk	4	0	0	4	40,41,66
Demographics	Race	Compared to white, Black have a greater risk	0	1	4	4	39,41,64,66
Pain chronicity	Chronic pain	Presence of chronic pain have greater risk	4	0	0	4	39-41
Medication use	Benzodiazepine use	Presence of benzodiazepine prescription vs none	2	1	0	3	39,40
Mental illness	Anxiety disorder	Presence of anxiety disorder, greater risk	2	0	1	3	39,66,71
Substance use issue	Tobacco	Tobacco or Smoking increases risk	3	0	0	3	40,66,71
Substance use issue	Alcohol or substance use disorder	Presence of alcohol or substance use disorder, greater risk	2	0	1	3	39,66,71
Mental illness	Depression	Presence of depression increases risk	1	0	2	3	39,64,71
Demographics	Race	Compared to white, Other/multiracial have a greater risk	0	2	3	3	39,41,64
Opioid use ^a	Opioid type	N/A				3	39,40

Comorbidities	Charleson comorbidities	Higher score, greater risk	1	0	1	2	66,71
Demographics	Race	Compared to white, Asian have a greater risk	0	1	2	2	41,66
Demographics	Race	Compared to white, Hispanic have a greater risk	0	1	1	2	41,66
Mental illness	Mood disorder	Presence of mood disorder, greater risk	1	0	1	2	66,71
Insurance	Type of insurance plan	compared to PPO, HMO coverage has greater risk	0	0	2	2	37,40
Substance use issue	Drug disorder	Presence of drug disorder has greater risk	2	0	0	2	40
Substance use issue	Alcohol dependence/abuse	Presence of alcohol dependence/abuse, greater risk	0	0	2	2	37,40
Medication use	Non opioid analgesic	Presence of non-opioid analgesic, greater risk	1	0	1	2	39,40
Surgery ^b	Surgery						37,66
Insurance	Type of insurance plan	compared to PPO, other coverage has greater risk	0	1	1	2	37,40
Mental illness	Mental health disorder (schizophrenia, mood disorders, neurotic disorders, and depression)	Presence of mental health disorder, greater risk	2	0	0	2	37,40
Utilization	Primary care visit (within 30 days)	Presence of primary care visit (within 30 days) has greater risk	1	1	0	2	41,71
Comorbidities	Asthma	Presence of asthma, greater risk	0	1	1	2	40,41
Pain diagnosis	Osteoporosis	Presence of osteoporosis, greater risk	1	0	1	2	40,41

This table only includes predictor variables that were in more than one model

^a Excludes variables that referenced opioid type, but models examined long-acting, tramadol, codeine, oxycodone, hydrocodone, hydrocodone

^b Excludes surgery related variables, but models examined Varicose Vein Removal, Laparoscopic Cholecystectomy, Laparoscopic Appendectomy, Hemorrhoidectomy, Thyroidectomy, Transurethral Prostate Surgery, Parathyroidectomy Carpal Tunnel, Ventral Incisional Hernia Repair, Colectomy Reflux, Surgery Bariatric Surgery, Hysterectomy, Nonoperative Comparisons, Carpal tunnel release, Carpometacarpal arthroplasty/arthrodesis, Cubital tunnel release, Trigger finger release, Closed distal radial fracture fixation, Flexor tendon repair, Metacarpal fracture fixation, Phalangeal fracture fixation

Studies with opioid-naïve sample^{37,39-41,64,66,71} Results from Koeppe 2011 are not included because definition of opioid-naïve sample differed from the other studies.⁷³

Figure 1: Prisma Flow Diagram

PRISMA 2009 Flow Diagram

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Karmali, RN;Bush, C;Raman, SR;Campbell, CI;Skinner, AC;Roberts, AW

Title:

Long-term opioid therapy definitions and predictors: A systematic review.

Date:

2020-03

Citation:

Karmali, R. N., Bush, C., Raman, S. R., Campbell, C. I., Skinner, A. C. & Roberts, A. W. (2020). Long-term opioid therapy definitions and predictors: A systematic review.. *Pharmacoepidemiol Drug Saf*, 29 (3), pp.252-269. <https://doi.org/10.1002/pds.4929>.

Persistent Link:

<http://hdl.handle.net/11343/286759>